ArticleOncology letters2015
Significance of gastrin-releasing peptide in ovarian cancer ES2 cells.
Article in Oncology letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 5 citations in OpenAlex.
- Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment.Expert opinion on therapeutic targets · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to investigate the effect of gastrin-releasing peptide (GRP) on the proliferation and invasion of ovarian cancer ES2 cells. The ovarian cancer ES2 cells were transfected with small interfering RNA against GRP. Cell proliferation was assessed using the Trypan blue assay, apoptosis was determined using propidium iodide/fluorescein isothiocyanate and flow cytometry, and the invasion ability was detected using the Transwell assay. The results revealed that the expression of GRP significantly decreased following transfection with GRP-short hairpin RNA. Furthermore, the silencing of GRP resulted in increased apoptosis and a reduced invasive ability of the ES2 cells. It was concluded that GRP may regulate the proliferation and migration of human ovarian cancer cells, which indicates that GRP may be a potential novel target for the treatment of ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.